Warnings, Columns-Drugs & Supplements, January 2006
January 20, 2006
Elidel and Protopic Labels Updated to Include Possible Cancer Risk WASHINGTON, D.C. - The Food and Drug Administration recently approved updated labels for eczema drugs Elidel and Protopic to include 'black box' warnings risk of cancer associated with the topical ointments. The FDA said on Jan. 19 that the boxed warning and medication guide will be distributed with Novartis Corp.'s Elidel Cream (pimecrolimus) and Astellas' Protopic Ointment (tacrolimus) to help ensure that patients are aware of the cancer risk. The new labels also clarify that these drugs are recommended for use as second-line treatments, the …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation ConferenceJanuary 10, 2025 - Long Beach, CA
The Westin Long Beach
|
